Nigeria has become the second country to authorize the use of a novel malaria vaccine

The Serum Institute of India's R21 malaria vaccine has been approved by the National Agency for Food and Drug Administration and Control.According to the Nigerian newspaper Punch NG, Prof. Mojisola Adeyeye, Director General of Nigeria's drug regulatory authority, NAFDAC, presented this information on Monday during a news conference in Abuja. Nigeria is now the second country to embrace the innovative malaria vaccine developed by the University of Oxford, following Ghana. Prof. Adeyeye recommends using the vaccination in children between the ages of 5 and 36 months to avoid the onset of clinical malaria. She stated that before the market authorization will begin making further arrangements with the National Primary Health Care Development Agency, the nation anticipates receiving at least 100,000 doses of the vaccine in contributions shortly.